Fluoxetina Accord

Quick links

Choose a section

Quick links to important sections

Advertisements

Fluoxetina Accord

Selected form

Advertisements
Advertisements

Overview of Fluoxetina Accord

What is Fluoxetina Accord?

Fluoxetina Accord is a medication that belongs to a group of medicines known as selective serotonin reuptake inhibitors (SSRIs). It is primarily used in the treatment of various mental health conditions by affecting the chemical balance in the brain.

Therapeutic Use

This medication is commonly used to treat adults for conditions such as:

  • Major Depressive Episodes: To help manage symptoms of persistent sadness and loss of interest.
  • Obsessive-Compulsive Disorder (OCD): To address repetitive thoughts and behaviors.
  • Bulimia Nervosa: Used as a complement to psychotherapy for the reduction of binge-eating and purging activities.

Use in Children and Adolescents

For children and adolescents aged 8 years and older, Fluoxetina Accord is used for:

  • Moderate to Severe Major Depressive Disorder: It is typically utilized when the condition does not respond to psychological therapy after 4 to 6 sessions.

Mechanism of Action

Everyone has a substance called serotonin in their brain. People who are depressed or have anxiety-related disorders may have lower levels of serotonin than others. While the exact process is complex, Fluoxetina Accord works by increasing the levels of serotonin available in the brain, which can help improve the symptoms associated with these conditions.

Regulatory References

  1. Fluoxetine: MedlinePlus Drug Information
Advertisements

What side effects are possible with Fluoxetina Accord?

Possible Side Effects and Safety Information

The safety profile of Fluoxetine, the active component in Fluoxetina Accord, is based on classifications and documentation from government regulatory authorities. Adverse reactions are grouped by frequency and the body system affected, known as the System Organ Class (SOC).

Very Common reactions (those affecting 1 in 10 or more patients) frequently involve the Nervous System and Gastrointestinal systems, including insomnia, headache, and nausea.

Common adverse reactions (affecting 1 in 100 to 1 in 10 patients) include symptoms such as anxiety, tremor, decreased libido, diarrhea, dry mouth, and excessive sweating.


Serious Adverse Reactions and Safety Constraints

Official labeling highlights the potential for several serious adverse reactions. These include the risk of Serotonin Syndrome, which is a potentially life-threatening condition, and the possibility of QT prolongation and ventricular arrhythmia in individuals with predisposing cardiac conditions. Severe allergic reactions that may begin as a rash are also documented safety concerns. Use is contraindicated with specific medications, such as irreversible, non-selective Monoamine Oxidase Inhibitors (MAOIs).


Time-Related and Population-Specific Safety

Regulatory documents emphasize specific safety patterns related to the timing of use. There is an increased risk of suicidal thinking and behavior in children, adolescents, and young adults during the initial months of therapy or following dose changes. For pediatric patients, long-term use necessitates the monitoring of growth and pubertal development. Individuals with hepatic impairment may require a lower or less frequent dosage due to decreased drug clearance, as noted in the official prescribing information.

Advertisements

Overdose and Emergency Response

Overdose with Fluoxetina Accord is officially documented by regulatory authorities as primarily involving central nervous system and cardiovascular toxicity, necessitating immediate clinical attention. Documented overdose presentations include seizures and hyperirritability, alongside cardiovascular signs such as tachycardia and potential for increased blood pressure. The severity of overexposure is defined by the risk of potentially life-threatening outcomes, including the development of Serotonin Syndrome and serious ventricular arrhythmia, such as Torsades de Pointes. Individuals must seek immediate medical attention when overdose is suspected or if these manifestations are present. Professional management is strictly required for stabilization. Official guidance mandates continuous ECG monitoring and assessment of vital signs to evaluate cardiac function. Emergency procedures focus on ensuring an adequate airway, oxygenation, and ventilation. Management is restricted to general supportive and symptomatic measures due to the officially stated fact that no specific antidotes for fluoxetine are known. Procedural interventions mentioned in regulatory documentation include the administration of activated charcoal and, in select cases, gastric lavage under appropriate protection; induction of emesis is not recommended.

Advertisements

Therapeutic Uses of Fluoxetina Accord

Fluoxetina Accord is commonly used across a range of conditions where additional symptomatic support is needed to support functional stability. The medication is generally applied in addressing symptom clusters associated with Major Depressive Disorder, Obsessive-Compulsive Disorder (OCD), Bulimia Nervosa, Panic Disorder, and Premenstrual Dysphoric Disorder (PMDD).

Fluoxetina Accord provides support that helps ease the overall symptom burden in situations involving certain distressing symptoms. It is used for managing disruptive manifestations like intrusive obsessions, debilitating low mood, and severe panic attacks. This application can assist with maintaining functional stability when symptoms interfere with routine activities.

“This medication is commonly used when short-term symptomatic assistance is needed across affective and anxiety-related domains.”

It is considered relevant in conditions characterized by periods of heightened symptoms, and may help patients cope more steadily with symptom fluctuations.


Quick Fact: Support for Mood and Anxiety Symptoms
Primary purpose Supports symptomatic comfort in chronic affective and anxiety-related conditions.
Symptom focus Low mood, panic attacks, obsessive thoughts, compulsive behaviors, and mood swings.
Usage context Applied during phases when symptoms become more noticeable and interfere with daily functioning.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Fluoxetina Accord?

Population eligibility for Fluoxetina Accord (Fluoxetine) is strictly defined by regulatory documents, categorizing use as prohibited, restricted, or established based on age, concurrent treatments, and physiological conditions.


Contraindications (Must Not Use)

  • Concurrent Drug Use: Use is absolutely prohibited in patients taking a Monoamine Oxidase Inhibitor (MAOI), including psychiatric MAOIs, linezolid, or intravenous methylene blue. This prohibition extends to 14 days after stopping an MAOI, and MAOIs must not be started until at least 5 weeks after stopping fluoxetine.
  • Other Prohibited Drugs: Use is contraindicated with concurrent pimozide or thioridazine.
  • Hypersensitivity: Patients with a known hypersensitivity to fluoxetine or any component of the medicine must not use it.

Age-Specific Eligibility and Restrictions

Population Group Regulatory Status
Adults Use is generally established for approved indications.
Adolescents (MDD) Use is established only for those aged 8 years and above.
Adolescents (OCD) Use is established only for those aged 7 years and older.
Geriatric (Older Adults) Use is conditional, often requiring a lower or less frequent dose.

Conditional Use and Special Populations

  • Hepatic Impairment: Use is restricted, often necessitating a lower or less frequent dose due to decreased clearance.
  • Pregnancy: Use is conditional, permitted only if the potential benefit justifies the potential risks to the fetus.
  • Breastfeeding: Use is not recommended due to the drug and its active metabolite being excreted in human milk.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Category Official Restriction/Entity
Contraindicated Combinations Monoamine Oxidase Inhibitors (MAOIs), Pimozide, Thioridazine, Linezolid, and Intravenous Methylene Blue are officially prohibited.
Pharmacokinetic Basis Fluoxetine is officially documented as a potent inhibitor of the CYP2D6 enzyme pathway, affecting drug clearance.
Timing Requirements A mandatory minimum of five weeks must elapse after discontinuing Fluoxetina Accord before initiating an MAOI or Thioridazine.
Population Consideration Hepatic Impairment may result in increased systemic drug exposure, a condition requiring administration schedule modification.

Official Interaction Statements

  • Co-administration with serotonergic agents, including Triptans, Tramadol, and the herbal product St. John's Wort, is associated with the officially documented risk of Serotonin Syndrome.
  • The potent inhibition of CYP2D6 can lead to officially documented increased plasma concentrations of certain co-administered drugs (e.g., specific Antipsychotics, Tricyclic Antidepressants, and Antiarrhythmics).
  • Concurrent use with Drugs that Interfere with Hemostasis, such as NSAIDs, Aspirin, or Warfarin, may potentiate the risk of bleeding.
  • Combination with drugs that prolong the QT Interval carries an increased risk of ventricular arrhythmia, including Torsades de Pointes.

Connection to the overall interaction profile

The regulatory interaction profile is defined by strict prohibitions targeting critical pharmacodynamic risks and mandatory timing constraints. The key pharmacokinetic concern is the documented inhibition of the CYP2D6 pathway, which results in elevated exposure of numerous co-administered medicines. All constraints are explicitly outlined in government prescribing information, which serves as the sole basis for these restrictions.

Advertisements

Mechanism of Action

Primary Action: Selective Serotonin Reuptake Inhibition (SSRI)

Fluoxetina Accord's main mechanism involves acting directly on the serotonin transporter (SERT) protein. It functions as a reuptake blocker, preventing the rapid removal of the neurotransmitter serotonin (5-HT) from the synaptic cleft. This inhibition causes an increase in serotonin's extracellular concentration, which leads to altered signal transduction across the synapse.


Functional Modifications of Serotonergic Signaling Pathways

The sustained elevation of serotonin levels initiates a downstream mechanistic cascade that leads to functional modifications within the entire serotonergic system. Over time, this mechanism modifies the activity of pathways exhibiting dysregulated neural signaling through the long-term adjustment of specific serotonin receptor sensitivity and density. This process engages intracellular signaling pathways and influences regulatory feedback loops within the neurons.


Physiological Regulation and Signal Adjustment

This targeted influence on key regulatory pathways alters physiological signaling dynamics within the central nervous system. The drug’s action adjusts signal density within these neural circuits and modifies the consequences of heightened mediator activity, establishing the drug's core pharmacodynamic effect profile.

Advertisements

Dosage and Administration Information

Administration Scope

Instruction Category Guideline
Route of administration The medicine is approved exclusively for oral administration.
Dosing schedule (Adults) Initial dosing for Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD) is typically 20 mg daily, which may be increased up to a maximum of 80 mg per day. Bulimia Nervosa uses a fixed dose of 60 mg daily. Panic Disorder starts at 10 mg daily before increasing to 20 mg.
Timing in relation to meals Administration is permitted with or without food, as meals do not significantly impact the absorption of the active substance.
Preparation requirements The oral solution formulation must be shaken well and measured precisely using a calibrated device to ensure correct dosage.
Age-group administration rules A lower or less frequent dosage is recommended for older adults (elderly) and patients with hepatic impairment. Pediatric dosing (age 8+) for MDD often initiates at 10 mg or 20 mg daily.
Missed-dose rules If a dose is missed, it should be taken as soon as the lapse is remembered, unless it is close to the time for the next scheduled dose.
Special procedural conditions Dosing is usually administered once a day in the morning. Doses exceeding 20 mg may be taken in a divided schedule (morning and noon). Premenstrual Dysphoric Disorder (PMDD) may utilize an intermittent cyclic regimen.

Instruction Classifications (High-Level)

Classification Type Summary of Pattern
Administration method type Oral.
Frequency pattern Daily, Twice-daily (divided dosing), or Intermittent/Cyclic.
Use-context constraints Dosage adjustments are only evaluated after several weeks (e.g., 3-4 weeks) due to the delayed full effect; maintenance treatment duration for MDD is typically at least 6 months.

Resulting Procedural Structure

Step sequence:

  • The drug is taken orally using one of the available dosage forms (capsule, tablet, or solution).
  • The medicine is administered once daily (or divided), usually in the morning, following the condition-specific milligram schedule.
  • The patient sustains the initial dose for several weeks before any dose increase is considered by the prescriber.
  • For certain conditions, the regimen follows a cyclic pattern, while maintenance treatment often requires long-term daily use.
  • Dosage modifications are required for specific populations, such as those with impaired liver function.

Connection to the overall use protocol: The usage protocol dictates a standardized oral administration and defines precise milligram ranges for initiation and maintenance across approved conditions. The requirement for a several-week review period for dosage adjustment establishes the timeframe needed for procedural modifications. Instructions for special populations and the intermittent schedule for PMDD reflect flexibility within a structured administration plan.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence

Clinical research on fluoxetine, the active substance in Fluoxetina Accord, primarily investigates its use in treating Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), and Bulimia Nervosa.

Studies consistently support the role of fluoxetine in the management of these conditions. The drug is classified as a selective serotonin reuptake inhibitor (SSRI).

Research Findings in Key Indications

Condition Research Focus and Findings Scope
Major Depressive Disorder (MDD) Trials examined the response rate and remission status in adults and adolescents. Findings generally showed that fluoxetine was associated with statistically significant improvement in validated mood scales compared to placebo. Short-term (4-8 weeks) and long-term (up to 12 months) trials.
Obsessive-Compulsive Disorder (OCD) Research focused on changes in the severity and frequency of obsessive thoughts and compulsive behaviors. Studies evaluated effectiveness across various symptom profiles, with high-dose regimens being investigated in some refractory cases. Multiple randomized, controlled trials.
Bulimia Nervosa Clinical studies explored the reduction in binge-eating and purging behaviors. Research was also conducted to examine the association between treatment and weight changes in patients. Specifically studied in adult populations.

Safety and Tolerance

Fluoxetine's safety profile has been extensively monitored over decades. Common adverse effects reported in clinical trials include nausea, insomnia, headache, and diarrhea, which are typically mild and often resolve with continued use. Serious adverse events are rare. Regulatory bodies emphasize that treatment should be monitored carefully, especially at the start of therapy, due to the observed, albeit rare, risk of suicidal thoughts and behaviors in young adults and adolescents.

Key Studies & References

  1. Fluoxetine Accord capsule, hard ENG PAR (Public Assessment Report)
  2. Fluoxetine - StatPearls (Medical monograph covering indications and dosing)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Fluoxetina Accord (FAQ)


Q: What is the difference between Fluoxetina Accord and Prozac?

Fluoxetina Accord is a generic medicine, meaning it contains the same active ingredient as the original brand-name drug. Prozac is the brand name originally given to the exact same active ingredient, which is fluoxetine. The official product information confirms they share the same core substance.


Q: Is Fluoxetina Accord the same type of medicine as sertraline or escitalopram?

Yes, they belong to the same pharmacological classification. The active ingredient in Fluoxetina Accord, fluoxetine, belongs to the class of medicines known as Selective Serotonin Reuptake Inhibitors (SSRIs). Other medicines like sertraline and escitalopram are also grouped under the SSRI classification, meaning they share a similar mechanism of action.


Q: How long does it typically take to start noticing any effect from Fluoxetina Accord?

Clinical studies indicate that an initial onset of therapeutic response may be noted by some patients around the second week of treatment. However, the full therapeutic benefit typically requires several weeks of consistent use to fully manifest and stabilize. This is why dosage adjustments are not evaluated immediately.


Q: Can Fluoxetina Accord cause changes in weight?

Official product information states that changes in weight have been reported as a potential side effect. Significant changes in weight, including both weight loss and weight gain, have been observed in clinical data.


Q: Is it common for people to feel restless or anxious when they first start taking Fluoxetina Accord?

Restlessness and anxiety are listed as common adverse effects reported in official drug labeling. Official regulatory guidance describes the requirement for close monitoring during the first few months of treatment for potential worsening of symptoms or the emergence of new symptoms.


Q: Can Fluoxetina Accord make existing anxiety feel worse initially?

Anxiety is a reported adverse reaction. Regulatory guidance requires close monitoring for any clinical worsening, including the emergence of agitation or irritability, especially at the start of treatment or following a change in dosage.


Q: Does Fluoxetina Accord interact with common over-the-counter pain relievers?

Concurrent use with over-the-counter pain relievers, particularly those classified as non-steroidal anti-inflammatory drugs (NSAIDs) and Aspirin, may increase the officially documented risk of bleeding. This is due to the potential for these medicines to interfere with the body’s ability to clot blood.


Q: Are there any specific foods or drinks to avoid while taking Fluoxetina Accord?

Official prescribing information generally contains a warning regarding the consumption of alcohol while taking fluoxetine. There are no specific restrictions listed regarding common foods.


Q: Does Fluoxetina Accord affect sleep patterns?

Yes, effects on sleep are commonly reported in official safety information. Insomnia (trouble sleeping) is specifically listed as a very common side effect, though increased sleepiness or drowsiness has also been reported by some patients.


Q: Are there different strengths of Fluoxetina Accord available?

The active ingredient, fluoxetine, is available in multiple dosage forms and strengths, according to official product labeling. This includes different capsule strengths, such as 10 mg, 20 mg, and 40 mg, as well as an oral solution formulation.


Q: What evidence supports the use of Fluoxetina Accord for panic disorder?

Fluoxetine is officially approved by regulatory bodies for the treatment of Panic Disorder. This approval is based on clinical trial data demonstrating the drug's efficacy for this specific indication.


Q: How quickly does the active ingredient (fluoxetine) leave the body?

Fluoxetine is officially documented as having a long elimination half-life, meaning it stays in the body for an extended time. The half-life for the active substance is documented to be 4 to 6 days, and its active metabolite can remain in the body for 4 to 16 days.


Q: Is Fluoxetina Accord habit-forming or addictive?

No. Fluoxetine is not classified as a controlled substance by regulatory authorities. The medicine does not have the physically addictive or abuse potential associated with benzodiazepines or opioids.


Q: Can Fluoxetina Accord be taken with vitamin supplements?

Official product information suggests that all co-administered products, including over-the-counter medicines, herbal products, or dietary supplements, should be reviewed by a healthcare provider. This is done to help identify any potential unintended interactions with the medication.


Q: Is it necessary to take Fluoxetina Accord at the exact same time every day?

The medication is typically administered once a day in the morning. Due to the active ingredient's long half-life, minor variations in the daily timing are not expected to be clinically significant. A consistent daily schedule is a typical part of the administration plan.


Q: Can Fluoxetina Accord be used safely during pregnancy?

Official guidance states that use during pregnancy may be permitted if the potential benefit to the patient justifies the potential risks to the fetus. Use during the late third trimester has been associated with complications in the newborn, such as short-term withdrawal symptoms, which may require monitoring.


Q: Can taking Fluoxetina Accord affect my ability to drive or operate machinery?

Any psychoactive medicine may potentially affect judgment, coordination, or thinking skills. Official information cautions that performance may be impaired, and patients should be aware of this risk before driving or operating hazardous machinery.


Q: Are there any known long-term effects on the heart from taking Fluoxetina Accord?

The medicine is associated with a risk of QT prolongation, which is a change to the heart's electrical rhythm. The official prescribing information describes a requirement for caution in patients with predisposing cardiac risk factors.


Q: Are there specific symptoms that require immediate medical attention while on Fluoxetina Accord?

Yes, official patient information describes that immediate medical attention is necessary if certain serious symptoms are observed. These include signs such as high fever, fast or abnormal heartbeat, severe agitation, hallucinations, or signs of a serious allergic reaction like sudden rash or swelling of the face or tongue.


Q: What is the average period of treatment with Fluoxetina Accord?

Official guidelines define treatment duration based on the condition being treated. For conditions like Major Depressive Disorder, maintenance treatment duration is generally defined as at least six months after a satisfactory initial response has been achieved.


Q: Does research show a difference in effectiveness based on the patient's age?

Clinical data suggests that age does not significantly alter the pharmacokinetics—the way the drug is processed by the body—of the active ingredient. However, official guidance requires consideration of a lower starting or less frequent dose for older adults.


Q: Can Fluoxetina Accord interact with medicines for blood pressure?

The official product label describes a requirement for caution when fluoxetine is used in patients with heart rhythm issues, including those related to electrolyte imbalance, which can be affected by certain blood pressure medicines. Caution is also required in patients with hypotension (low blood pressure).


Q: What should be done before starting Fluoxetina Accord to check for eligibility?

Before prescribing, a doctor may evaluate a patient's risk factors for a heart rhythm condition called QTc prolongation, sometimes utilizing an ECG test. They may also evaluate patients for pre-existing bipolar disorder before treatment initiation.


Q: Can Fluoxetina Accord be taken with antacids?

Fluoxetine is documented as being highly bound to plasma proteins in the blood. Although antacids are not specifically listed as a contraindication, official information states that all co-administered drugs and supplements should be reviewed by a prescriber.


Q: Does Fluoxetina Accord affect hormonal birth control?

Current research indicates that fluoxetine does not significantly affect the safety or effectiveness of hormonal birth control. A review of hormonal birth control use with a healthcare provider is generally part of the overall treatment review, and observation for any adverse events is advised.


Q: Are there official guidelines for monitoring patients taking Fluoxetina Accord?

Yes, official guidelines require close monitoring for clinical worsening and suicidality during the initial months of therapy. In individuals with high-risk heart conditions, specialized monitoring like an ECG and electrolyte tests may also be required.

Advertisements

How should Fluoxetina Accord be stored and disposed of?

Storage and Disposal Conditions for Fluoxetina Accord

Storage of Fluoxetina Accord capsules must adhere to specific regulatory mandates to ensure stability. The product is required to be stored at Controlled Room Temperature, typically defined as 20°C to 25°C, with a maximum limit not exceeding 30°C.

To protect the medicine, it must be stored in its original container and kept closed tightly, thereby guarding against light and moisture. The official shelf life for the capsules is up to 3 years in blister packs when stored correctly.

For safety, the medication must be kept out of the reach and sight of children.

All unused or expired Fluoxetina Accord, including waste material, must be disposed of in accordance with local requirements established by health authorities to protect the environment and public health.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fluoxetina Accord found in:

A-Z Index: